Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul;32(5):442-58.
doi: 10.1002/dmrr.2827.

Standards of care for type 2 diabetes in China

Jianping Weng  1 , Linong Ji  2 , Weiping Jia  3 , Juming Lu  4 , Zhiguang Zhou  5 , Dajin Zou  6 , Dalong Zhu  7 , Liming Chen  8 , Li Chen  9 , Lixin Guo  10 , Xiaohui Guo  11 , Qiuhe Ji  12 , Qifu Li  13 , Xiaoying Li  14 , Jing Liu  15 , Xingwu Ran  16 , Zhongyan Shan  17 , Lixin Shi  18 , Guangyao Song  19 , Liyong Yang  20 , Yuzhi Yang  21 , Wenying Yang  22 ; Chinese Diabetes Society
Affiliations

Standards of care for type 2 diabetes in China

Jianping Weng et al. Diabetes Metab Res Rev. 2016 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
The treatment algorithm for high blood glucose in T2DM. The blue paths are the recommended primary drug treatment paths based on comprehensive considerations, including clinical evidence of the drug's health economics, efficacy and safety and China's national conditions. These paths are similar to the drug treatment pathways recommended by most international diabetes guidelines. The orange paths are alternative paths for the corresponding blue paths. HbA1c, glycated haemoglobin; DPP‐4, dipeptidyl peptidase IV; TZD, thiazolidinedione; GLP‐1, glucagon‐like peptide‐1
Figure 2
Figure 2
Insulin treatment paths for T2DM. HbA1c, glycated haemoglobin; FPG, fasting plasma glucose; CSII, continuous subcutaneous insulin infusion
Figure 3
Figure 3
The clinical decision‐making paths for screening and the standard lipid‐lowering, antihypertensive and antiplatelet treatments for patients with T2DM. ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor antagonist; LDL‐C, low‐density lipoprotein cholesterol
See this image and copyright information in PMC

References

    1. National Diabetes Study Group . A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China. Zhonghua Nei Ke Za Zhi 1981; 20(11): 678–683. - PubMed
    1. Pan XR, Yang WY, Li GW, et al., Prevalence of diabetes and its risk factors in China, 1994 . National Diabetes Prevention and Control Cooperative Group. Diabetes Care 1997; 20(11): 1664–1669. - PubMed
    1. Li LM, Rao KQ, Kong LZ, et al. A description on the Chinese national nutrition and health survey in 2002. Zhonghua Liu Xing Bing Xue Za Zhi 2005; 26(7): 478–484. - PubMed
    1. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362(12): 1090–1101. - PubMed
    1. Chinese Diabetes Society . China guideline for type 2 diabetes (2010). Chin J Diabetes 2012; 20(1): S1–S36.